Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. 02197
02197 logo

02197 Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
2.900
Open
2.680
VWAP
2.85
Vol
10.04M
Mkt Cap
--
Low
2.680
Amount
28.56M
EV/EBITDA(TTM)
--
Total Shares
--
EV
404.61M
EV/OCF(TTM)
--
P/S(TTM)
860.14

Events Timeline

No data

No data

News

PRnewswire
9.0
01-12PRnewswire
Clover Initiates Phase 2 Trial for RSV Vaccine, Enrolling 420 Participants
  • Trial Initiation: Clover Biopharmaceuticals has completed enrollment of the first participants in a Phase 2 clinical trial in Australia for its protein-based vaccine candidates SCB-1022 and SCB-1033, aiming to recruit up to 420 older adults aged 60 to 85 to assess vaccine safety and immunogenicity, thereby enhancing its global first-in-class potential.
  • Combination Vaccine Advantage: The trial will evaluate SCB-1022 and SCB-1033, which target RSV and hMPV, with the latter also including PIV3, addressing significant unmet needs for vaccine protection globally, particularly for individuals previously vaccinated against RSV to restore their immunity.
  • Validated Technology Platform: Clover's vaccine candidates utilize its validated Trimer-Tag technology platform, showcasing its innovative capabilities in vaccine development, which may significantly reduce the burden of vaccine-preventable diseases and strengthen its competitive position in the biotechnology sector.
  • Global Market Potential: CEO Joshua Liang stated that the initiation of this Phase 2 trial represents a critical milestone in the company's R&D process and could open new growth opportunities in the vaccine market, particularly among the elderly population, enhancing the strategic importance of the company in the global vaccine landscape.
Wall Street analysts forecast 02197 stock price to rise
0 Analyst Rating
Wall Street analysts forecast 02197 stock price to rise
0 Buy
0 Hold
0 Sell
Current: 0.000
sliders
Low
Averages
High
Current: 0.000
sliders
Low
Averages
High
No data

No data

Valuation Metrics

The current forward P/E ratio for (02197.HK) is 56.10, compared to its 5-year average forward P/E of 9.66. For a more detailed relative valuation and DCF analysis to assess 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
9.66
Current PE
56.10
Overvalued PE
29.48
Undervalued PE
-10.17

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
1.01
Current EV/EBITDA
15.65
Overvalued EV/EBITDA
6.37
Undervalued EV/EBITDA
-4.34

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.82
Current PS
3.90
Overvalued PS
16.58
Undervalued PS
-6.95

Financials

AI Analysis
Annual
Quarterly

Whales Holding 02197

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is (02197) stock price today?

The current price of 02197 is 2.85 USD — it has increased 6.34

What is (02197)'s business?

What is the price predicton of 02197 Stock?

Wall Street analysts forecast 02197 stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for 02197 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is (02197)'s revenue for the last quarter?

revenue for the last quarter amounts to NaN USD, decreased

What is (02197)'s earnings per share (EPS) for the last quarter?

. EPS for the last quarter amounts to USD, decreased

How many employees does (02197). have?

(02197) has 0 emplpoyees as of April 03 2026.

What is (02197) market cap?

Today 02197 has the market capitalization of 0.00 USD.